Life sciences-focused investment firm TCG Crossover, based in Palo Alto, CA, and NYC, USA, has successfully closed its second fund, TCGX Fund II, with $1 billion in capital. The fund attracted support from both new and existing limited partners, with commitments coming from investors worldwide, including North America, Europe, the Middle East, and Asia. The substantial fund closure underscores TCG Crossover's strong position in life sciences investment and its global appeal to investors seeking opportunities in the sector.